Diagenode Announces Acquisition of Service Provider NXT-Dx to Complement Epigenetics Assay Services
DENVILLE, N.J. and LIEGE, Belgium (PRWEB) August 16, 2018 -- Diagenode today announced the acquisition of NXT-Dx, an established epigenetics service provider based in Gent, Belgium. NXT-Dx provides a broad variety of start-to-finish epigenetics services including a number of targeted DNA methylation assays using pyrosequencing or Next-Generation Sequencing and Illumina’s Infinium Methylation EPIC array. These technologies enable a more targeted approach for the screening of DNA methylation biomarkers. In addition, NXT-Dx offers chromatin and mRNA wet-lab and analysis services.
“We are pleased to add NXT-Dx’s expertise to our growing epigenomics services platform,” stated Didier Allaer, CEO of Diagenode. “The services offered by NXT-Dx perfectly complement Diagenode’s current chromatin, RNA, and DNA methylation assay services and will allow researchers to focus both on discovery and validation of epigenetic signatures.” Allaer also added, “Additionally, the targeted DNA methylation analyses that NXT-Dx offers now close the gap between epigenetics and IVD assay development.”
The added NXT-Dx services give researchers access to easier screening of large patient populations to develop and validate DNA methylation signatures and will broaden Diagenode’s role in epigenetic biomarker discovery.
“We are excited to be enhancing Diagenode’s service portfolio via this acquisition of our complementary services,” said Maarten Braspenning, CEO of NXT-Dx. “With the combined expertise, we can now offer full end-to-end services for IVD screening of biomarkers and clinical validation of DNA methylation signatures.”
To learn more about Diagenode’s Epigenomics Assay Services, visit https://www.diagenode.com/en/categories/Services.
Learn more about NXT-Dx at http://www.nxt-dx.com/.
Diagenode:
Diagenode is a leading provider of complete solutions for epigenetics research and sample preparation. The company has developed both shearing solutions for a number of applications as well as a comprehensive approach to gain new insights into epigenetics studies. The company offers innovative DNA and chromatin shearing and automation instruments, reagent kits, and high quality antibodies to streamline DNA methylation, ChIP, and ChIP-seq workflows. The company’s latest innovations include the industry’s most validated ChIP antibodies, CATS-based RNA sequencing, and epigenetics assay services. For more information about Diagenode, please visit the company’s website at http://www.diagenode.com.
R Saxena, Diagenode, Inc., +1 (858) 774-7501, [email protected]
Share this article